Cleared Traditional

K193299 - VITEK 2 AST-Gram Negative Ceftazidime (=<0.5 - =>32 µg/mL) (FDA 510(k) Clearance)

Sep 2020
Decision
306d
Days
Class 2
Risk

K193299 is an FDA 510(k) clearance for the VITEK 2 AST-Gram Negative Ceftazidime (=<0.5 - =>32 µg/mL). This device is classified as a System, Test, Automated, Antimicrobial Susceptibility, Short Incubation (Class II - Special Controls, product code LON).

Submitted by bioMerieux, Inc. (Hazelwood, US). The FDA issued a Cleared decision on September 28, 2020, 306 days after receiving the submission on November 27, 2019.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.1645.

Submission Details

510(k) Number K193299 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 27, 2019
Decision Date September 28, 2020
Days to Decision 306 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LON - System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.1645

Similar Devices - LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation

All 26
VITEK 2 AST-Streptococcus Cefuroxime (<=0.125 - >=8 µg/mL)
K260281 · BIOMERIEUX · Mar 2026
VITEK 2 AST-Gram Negative Cefazolin (=<1-=>32 µg/mL)
K251579 · bioMerieux, Inc. · Aug 2025
BD Phoenix Automated Microbiology System - GN Eravacycline (0.125-2 µg/mL)
K251713 · Becton, Dickinson and Company · Aug 2025
BD Phoenix™ Automated Microbiology System - GN Imipenem-relebactam (0.0625/4 - 16/4 µg/mL)
K250447 · Becton, Dickinson and Company · May 2025
VITEK COMPACT PRO
K234012 · bioMerieux, Inc. · Mar 2025
BD Phoenix™ Automated Microbiology System
K250344 · Becton, Dickinson and Company · Mar 2025